Both in R&D — Physical & Biological Sciences
Incyte Genomics vs IB Acquisition
Over the past year INCY returned +14.1% and IBAC returned +3.7%; their daily moves had a correlation of -0.03.
INCY +14.1% IBAC +3.7%Growth of $1, one year, split-adjusted
| Metric | INCY | IBAC |
|---|---|---|
| Price | $118.01 | $10.81 |
| Market cap | $24.05B | $54.1M |
| Today | −3.94% | −0.46% |
| 1 month | +4.0% | −0.6% |
| 6 months | +20.7% | −0.2% |
| Year to date | +19.5% | +3.0% |
| 1 year | +14.7% | — |
| Revenue growth (YoY) | +14.0% | — |
| Gross margin | 93.0% | — |
| Net margin | −50.4% | — |
| P/E (TTM) | 59.6× | — |
| Price / sales | 4.0× | — |
| Net cash | $3.82B | — |
| Dividend yield | — | — |
| Volatility (60d) | 29.8% | 20.1% |
| Short % of float | 5.9% | 0.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).